ClinicalTrials.gg
CompletedNCT03621956MINVINIRSUpdated Jul 8, 2024Results posted

Cardiac and Cerebral Hemodynamics With Umbilical Cord Milking Compared With Early Cord Clamping

An interventional study of Umbilical Cord Milking and Early Cord Clamping in Birth Asphyxia With Neurologic Involvement, sponsored by Sharp HealthCare. Completed at 3 sites in 2 countries. Open to participants aged 35 Weeks to 42 Weeks. Per ClinicalTrials.gov, last updated 2024-07-08.

Sponsored by Sharp HealthCare · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
35 Weeks to 42 Weeks
Sex
All
01

Study summary

3 clinical sites enrolling in the primary MINVI trial (NCT03631940) will collect Near Infrared Spectroscopy (NIRS) data in the first 10 minutes of life on a subset of 200 non-vigorous term and near-term infants enrolled in the trial.

Read the detailed description

Rationale: Caregivers and researchers raised theoretical concerns that the UCM technique may deliver blood rapidly toward a non-vigorous newborn predisposing them to higher rates of brain injury or dislodging cellular debris into the brain. However, of the 13 studies on term infants comparing UCM to ECC, none have reported adverse outcomes. Even in more fragile preterm infants, no harm has been reported. All demonstrated improvements similar to DCC with increased red cell mass (measured by hematocrit or hemoglobin) improved blood pressure, increased pulmonary blood flow and improved ferritin at 6 weeks to 6 months of age with UCM. Nevertheless, careful assessment of safety is essential. Immediate physiological measurements on a subset (n=200) of infants of the two sub-study sites where the use of NIRS is standard of care, University of Alberta and SMBHWN, to establish the safety and efficacy of UCM. This aim will further test our hypotheses that infants in the UCM group will have improved early cardiac and cerebral hemodynamics within the first 10 minutes.

The Near-infrared spectroscopy (NIRS) is a technology that allows non-invasive continuous real-time measurement of the regional tissue oxygen saturation (StO2) of organs such as the brain. There are well-established reference cerebral StO2 values for uncomplicated term and preterm deliveries; however, there are no completed RCTs using NIRS in the delivery room. Our group is currently leading the first multicenter trial (1R01HD088646-01A1) comparing DCC and UCM measuring NIRS at birth in premature infants. If cerebral oxygenation is improved, it will provide one plausible explanation for the long-term benefits expected with UCM. While published data exists on cerebral oxygenation directly comparing UCM with DCC, some studies demonstrated increases in cerebral oxygenation at 4 hours of age with DCC, and a decrease in cerebral oxygenation at birth with DCC compared to immediate cord clamping. To our knowledge, no studies using cerebral oxygenation in non-vigorous term/near-term infants have ever been performed. This sub-study (n=200) will yield the largest available sample of specific measurements of cerebral oximetry in non-vigorous term newborns.

Substudy Sites: Three sites experienced with NIRS (University of Alberta, Sharp Grossmont Hospital and SMBHWN) will obtain and report the physiological changes with UCM and ECC at 10 minutes of life. Data from the non-invasive monitoring devices are recorded using a continuous real-time data acquisition system that provides a second-by-second record of the resuscitation that is also time-linked to the video recordings. Both sites have 24/7 research team coverage that attend all high-risk deliveries. The research team will ensure accurate sensor placement and data collection. These two exceptional settings will allow us to collect significant data regarding resuscitation outcomes linked to cerebral oxygenation.

Protocol for NIRS Sub-Study: At the two sub-study sites, the use of NIRS is standard of care.

As part of the NIRS sub-study, sites will collect physiological and resuscitation data from birth (mean airway pressure, fractional oxygen) in addition to cerebral oxygenation. Once the newborn is delivered, receives the intervention (UCM or ECC), and is stabilized during resuscitation, a NIRS sensor (Fore-Sight, CAS Medical, Branford, CT) will be placed on the right forehead within 10 minutes of the newborn being placed on the warmer. While arterial saturation and heart rate data will be available to the clinical team, data from NIRS will be blinded. Data on all study infants will be recorded for the first 10 minutes in the delivery room at the two sites. Heart rate, oxygen saturations, and cerebral oxygenation will be downloaded as per both site's practice for neonatal resuscitation.

02

Conditions studied

  • Birth Asphyxia With Neurologic Involvement

Browse trials for

Keywords

  • Near-Infrared Spectroscopy
03

In context

Asphyxia

39 studies on the registry are indexed under Asphyxia; 7 are open to participants now.

This study's enrollment of 34 is below the median of 111 across 24 interventional studies indexed under Asphyxia.

Browse Asphyxia studies →

Lead sponsor

Sharp HealthCare is the lead sponsor of 40 studies on the registry; 4 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Weeks to 42 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-vigorous newborns born between 35-42 weeks gestation
  • Born at NIRS Sub-study site

Exclusion criteria

Exclusion Criteria:

  • Known major congenital or chromosomal anomalies of newborn
  • Known cardiac defects other than small ASD, VSD and PDA
  • Complete placental abruption/cutting through the placenta at time of delivery
  • Monochorionic multiples
  • Cord Avulsion
  • Presence of non-reducible nuchal cord
  • Perinatal providers unaware of the protocol
  • Incomplete delivery data Infants born in extremis, for whom additional treatment will not be offered
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Active comparator
    Umbilical Cord Milking

    At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.

    Procedure: Umbilical Cord Milking

  • Active comparator
    Early Cord Clamping

    The umbilical cord is clamped within 30 seconds of delivery.

    Procedure: Early Cord Clamping

Interventions

  • ProcedureUmbilical Cord Milking

    At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.

  • ProcedureEarly Cord Clamping

    The umbilical cord is clamped within 30 seconds of delivery.

06

What researchers measure

Primary outcomes

  1. StO2 in the First 10 Minutes of Life

    Cerebral oxygenation derived from skeletal muscle oxygen saturation (StO2) measured by near-infrared spectroscopy (NIRS). Once the newborn is delivered, receives the intervention (UCM or ECC), and is stabilized during resuscitation, a NIRS sensor (Fore-Sight, CAS Medical, Branford, CT) will be placed on the right forehead within 10 minutes of the newborn being placed on the resuscitation bed.

    Time frame: birth to 10 minutes of life

Secondary outcomes

  1. Heart Rate at 10 Minutes

    Heart rate was recorded from the electrocardiogram monitor.

    Time frame: Birth to 10 minutes of life

07

Results

Posted Jul 8, 2024

Participant flow

Participant flow — Overall Study
MilestoneUmbilical Cord MilkingEarly Cord Clamping
Started1519
Completed1519
Not completed00

Outcome measures

PrimaryStO2 in the First 10 Minutes of Life

Cerebral oxygenation derived from skeletal muscle oxygen saturation (StO2) measured by near-infrared spectroscopy (NIRS). Once the newborn is delivered, receives the intervention (UCM or ECC), and is stabilized during resuscitation, a NIRS sensor (Fore-Sight, CAS Medical, Branford, CT) will be placed on the right forehead within 10 minutes of the newborn being placed on the resuscitation bed.

Time frame:
birth to 10 minutes of life
Reported as:
Mean · percent
StO2 in the First 10 Minutes of Life
percentUmbilical Cord MilkingEarly Cord Clamping
StO2 in the First 10 Minutes of Life70 ± 7.1574.5 ± 2.17
SecondaryHeart Rate at 10 Minutes

Heart rate was recorded from the electrocardiogram monitor.

Time frame:
Birth to 10 minutes of life
Reported as:
Mean · Beats per minute
Heart Rate at 10 Minutes
Beats per minuteUmbilical Cord MilkingEarly Cord Clamping
Heart Rate at 10 Minutes152 ± 12.76160 ± 12.99

Adverse events

Collected over The first 10 minutes of life.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Umbilical Cord Milking0/15 (0%)0/15 (0%)0/15 (0%)
Early Cord Clamping0/19 (0%)0/19 (0%)0/19 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Umbilical Cord MilkingEarly Cord ClampingTotal
<=18 years151934
Between 18 and 65 years000
>=65 years000
Age, Continuous
Age, Continuous(Gestational Age in weeks)Umbilical Cord MilkingEarly Cord ClampingTotal
Mean38.13 ± 1.5638.95 ± 1.7238.54 ± 0.41
Sex: Female, Male
Sex: Female, Male(Participants)Umbilical Cord MilkingEarly Cord ClampingTotal
Female61016
Male9918
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Umbilical Cord MilkingEarly Cord ClampingTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Umbilical Cord MilkingEarly Cord ClampingTotal
Canada10010
United States51924
08

Study locations

3 sites
  • Sharp Grossmont Hospial
    San Diego, California 91942, United States
  • Sharp Mary Birch Hospital for Women and Newborns
    San Diego, California 92123, United States
  • Governors of University of Alberta
    Edmonton, Alberta T6G 2R3, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Jun 2021, 28 months.

Results were first posted in Jul 2024, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2018
First posted
Aug 9, 2018
StartActual
Jan 7, 2019
Primary completionActual
Jun 1, 2021
CompletionActual
Dec 26, 2022
Results first posted
Jul 8, 2024
Last update
Jul 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03621956
Lead sponsor
Sharp HealthCare
Collaborators
Sharp Mary Birch Hospital for Women & Newborns
Responsible party
Anup Katheria, M.D. (Director, Neonatal Research Institute, Sharp HealthCare) — Principal investigator
First posted
Aug 9, 2018
Start date
Jan 7, 2019
Primary completion
Jun 1, 2021
Completion
Dec 26, 2022
Results posted
Jul 8, 2024
Last update
Jul 8, 2024

Study contacts

Anup Katheria, MD
principal investigator · Sharp Mary Birch Hospital for Women & Newborns

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion